Proactive investorsLogo Proactive Investors UK Website

Search field

1 year chart

digital-look imported chart image

1 day chart

digital-look imported chart image
Epic & Msn data
Epic AMP
Time: 16:30:10
Mid Price: 12.75
Change Today: 0.00
Change % Today: 0.00
Fifty Two Week High: 18.25
Fifty Two Week Low: 10.50
Market Capital: 16.88
Period & price data
Period Price
Now: 12.75
3 Months ago:
6 Months ago:
1 Year ago:
Additional information
Additional Information
Market: AIM
Sector: Pharmaceuticals & Biotechnology
Epic: AMP
News: Latest news
Web Site: Amphion Innovations
Other Articles: 02-02-201019-01-201012-01-2010

Amphion Innovations

Amphion builds shareholder value in high growth companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK.

Amphion has a significant shareholding in 8 Partner Companies developing proven technologies targeting substantial commercial marketplaces, each in excess of $1 billion. Each Partner Company is chosen with the goal of achieving an exit valuation in excess of $100 million.

CLICK HERE FOR FULL ANLAYSIS OF AMPHION INNOVATIONS
Tuesday, November 24, 2009

Amphion investee WellGen recognized as nutraceutical innovator by Global Business Insights

company news image

IP commercialisation company Amphion Innovations (AIM: AMP) has announced that its investee company WellGen Inc was recognised as an innovator in Global Business Insights’ newly released report “Key Players and Innovative Start-Ups in Nutraceuticals,” which analysed companies engaged in commercialising nutraceuticals including household names like Nestle, Danone, Abbott, DSM and Provexis.


The report by Business Insights, which is one of the major providers of strategic analysis of innovation in health and wellness, described the WellGen business model and WellGen’s first medical product, a theaflavin rich black tea concentrate (WG0401) the following way: (WG0401) is an anti-inflammatory agent that, among other effects, decreases expression of cyclooxygenase-2 (COX-2). COX-2 was the target of multi-billion dollar pharma compounds such as Vioxx, which has been withdrawn from the market for safety reasons. In contrast to Vioxx, WG0401 modulates a number of pro- and anti-inflammatory genes essential to help the body respond to and recover from inflammatory challenges such as intense exercise or illness.”


Medical foods were identified as a potential growth area for the future for reasons including the advancement of medical food technology, providing better tasting and better texture medical foods, opportunities to expand the consumer base of a medical food based on benefits that are relevant to other populations and advances in science, that will continue linking more diseases to diet and nutrition.


“We are delighted that WG has been recognized as an innovator by strategic market experts. We are determined to bring value to consumers, health care professionals, and our investors by employing our technology to discover and develop safe medical food products that address major inflammatory diseases,” said Chief Executive of WellGen Roddy Carter.


The pharma-like research conducted innovative players like WellGen demonstrated the value of their medical foods and products, enabling them to publicize more of the research to establish the nature of the effect of the nutraceutical in treating, preventing or curing a disease state, said the report.


The industry is projected to take off once a few such companies achieve success by applying this model, turning them into attractive acquisition targets or possibly significant strategic players offering licensing opportunities for the largest food and ingredients companies in near future.


Amphion holds a 14.6% stake in WellGen. Its other investments include Firestar Software (15.3%), Axcess International (8.5%), Motif Biosciences (38.5%), MSA Holdings B.S.C. (50%), M2M Imaging Corp (24.4%), Myconostica (22%), Private Markets (25%), Kromek (19.99%) and DataTern (100%).

NewsNow icon AddThis Feed Button
Register here to be notified of future Amphion Innovations articles.

Other Amphion Innovations articles

More articles ►

Other Amphion Innovations news

More news ►

Investors interested in Amphion Innovations recently viewed


No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.